Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials
Obesity Reviews · 2024-09 · 25 (9)
DOI: 10.1111/obr.13792 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Obesity Reviews, online erschienen am 23.06.2024. Verfasst von Sharath Kommu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Medicine, Marshfield Clinic Health System, Rice Lake, Wisconsin, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Weight Loss, Randomized Controlled Trials as Topic, Obesity. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Semaglutide is found to be efficient for weight loss in patients with overweight or obesity with diabetes mellitus (DM). With a wide range of adverse events reported, the efficacy and safety of once‐weekly subcutaneous semaglutide in individuals without DM, with overweight or obesity, is unclear. We conducted a comprehensive meta‐analysis of randomized studies on once‐weekly semaglutide in this patient population. We identified nine studies with 11,641 patients in the semaglutide group and 10,479 in the placebo group. We observed that semaglutide resulted in significant benefits, including change in body weight (%): mean difference (MD) of −11.49% ( p < 0.0001), change in absolute body weight: MD of −11.74 kg ( p < 0.0001), and change in waist circumference: MD of −9.06 cm ( p < 0.0001). Gastrointestinal side effects are predominant including nausea: odds ratio (OR) of 4.06 ( p < 0.0001), vomiting: OR of 4.43 ( p < 0.0001), diarrhea: OR of 2.10 ( p < 0.0001), constipation: OR of 2.43 ( p < 0.0001), gallbladder disorders: OR of 1.26 ( p = 0.010), and cholelithiasis: OR of 2.06 ( p = 0.04). Serious adverse events were not statistically significant: OR of 1.06 ( p = 0.82). However, the percentage of participants discontinuing due to adverse events and gastrointestinal side effects was statistically significant: ORs of 2.22 ( p < 0.0001) and 3.77 ( p < 0.0001), respectively. This study shows that in patients with overweight or obesity without DM, once‐weekly subcutaneous semaglutide can significantly decrease body weight without risk of serious adverse events when compared with a placebo. However, gastrointestinal side effects are predominant with semaglutide, which can result in medication discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hospital Medicine, Marshfield Clinic Health System, Rice Lake, Wisconsin, USA.
- Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
- Office of Research Computing and Analytics, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
ORCID-Profile: Sharath Kommu, Richard L Berg
Förderung
- NCATS NIH HHS
- Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS)
Zitieren
APA
Kommu, S., & Berg, R. L. (2024). Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials. Obesity Reviews, 25(9). https://doi.org/10.1111/obr.13792
Vancouver
Kommu S, Berg RL. Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials. Obesity Reviews. 2024;25(9). doi:10.1111/obr.13792
BibTeX
@article{Kommu2024,
author = {Kommu, Sharath and Berg, Richard L},
title = {Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials},
journal = {Obesity Reviews},
year = {2024},
volume = {25},
number = {9},
doi = {10.1111/obr.13792}
}
EUVIMED